Study protocol: a prospective controlled clinical trial to assess surgical or medical treatment for paediatric type 2 diabetes (ST2OMP)

Amy S Shah, Michael A Helmrath, Thomas H Inge, Stavra A Xanthakos, Megan M Kelsey, Todd Jenkins, Andrew T Trout, Lorna Browne, Kristen J Nadeau, Amy S Shah, Michael A Helmrath, Thomas H Inge, Stavra A Xanthakos, Megan M Kelsey, Todd Jenkins, Andrew T Trout, Lorna Browne, Kristen J Nadeau

Abstract

Introduction: The pathophysiology of type 2 diabetes (T2D) in youth differs from adults and conventional medical treatment approaches with lifestyle change, metformin, thiazolidinediones or insulin are inadequate. Metabolic bariatric surgery (MBS) improves multiple health outcomes in adults with T2D. Initial small, uncontrolled studies of Roux-en-Y gastric bypass have also suggested beneficial effects in adolescents. Definitive studies in youth with T2D are lacking, especially with the now more common form of MBS, vertical sleeve gastrectomy (VSG). The surgical or medical treatment for paediatric type 2 diabetes (ST2OMP) clinical trial was designed to test the hypothesis that VSG will more effectively reduce hyperglycaemic and diabetes comorbidities than the best currently available medical treatment incorporating state of the art pharmacotherapies. ST2OMP is also designed to better understand the pancreatic and enterohepatic mechanisms by which MBS improves diabetes and its associated comorbidities.

Methods and analysis: ST2OMP is a prospective, open-label, controlled clinical trial that will recruit 90 postpubertal participants, age range 13-19.9 years, with body mass index ≥35 kg/m2 or >120% of 95th percentile and youth-onset T2D. The primary outcome is the per cent of youth achieving haemoglobin A1c <6.0% at 12 months postgroup allocation (post-VSG vs postmedical group allocation). Secondary outcomes include remission of comorbidities and measures of β-cell and incretin responses at 12 and 24 months post VSG versus AMT.

Ethics and dissemination: The ST2OMP protocol was approved by the Cincinnati Children's Hospital Medical Center and the University of Colorado Institutional Review Boards. Written informed consent is obtained prior to study enrolment. Study findings will be widely disseminated through peer-reviewed publications and conference presentations.

Trial registration number: Clinical Trials.Gov NCT04128995.

Keywords: lipid disorders; paediatric endocrinology; paediatric surgery.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Overview of the Surgical or Medical Treatment for Paediatric Type 2 Diabetes (ST2OMP) study design showing run-in and treatment phases as well as frequencies and timings of study visits.

References

    1. Hamman RF, Bell RA, Dabelea D, et al. . The search for diabetes in youth study: rationale, findings, and future directions. Diabetes Care 2014;37:3336–44. 10.2337/dc14-0574
    1. Badaru A, Klingensmith GJ, Dabelea D, et al. . Correlates of treatment patterns among youth with type 2 diabetes. Diabetes Care 2014;37:64–72. 10.2337/dc13-1124
    1. TODAY Study Group, Zeitler P, Hirst K, et al. . A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247–56. 10.1056/NEJMoa1109333
    1. TODAY Study Group . Longitudinal changes in cardiac structure and function from adolescence to young adulthood in participants with type 2 diabetes mellitus: the today follow-up study. Circ Heart Fail 2020;13:e006685. 10.1161/CIRCHEARTFAILURE.119.006685
    1. Shah AS, El Ghormli L, Gidding SS, et al. . Prevalence of arterial stiffness in adolescents with type 2 diabetes in the today cohort: relationships to glycemic control and other risk factors. J Diabetes Complications 2018;32:740–5. 10.1016/j.jdiacomp.2018.05.013
    1. Bjornstad P, Nehus E, El Ghormli L, et al. . Insulin sensitivity and diabetic kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. Am J Kidney Dis 2018;71:65–74. 10.1053/j.ajkd.2017.07.015
    1. RISE Consortium . Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. observations using the oral glucose tolerance test. Diabetes Care 2018;41:1707–16. 10.2337/dc18-0243
    1. RISE Consortium, RISE Consortium Investigators . Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults. Diabetes 2019;68:1670–80. 10.2337/db19-0299
    1. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. . Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med 2019;381:637–46. 10.1056/NEJMoa1903822
    1. Arslanian S, Bacha F, Grey M, et al. . Evaluation and management of Youth-Onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care 2018;41:2648–68. 10.2337/dci18-0052
    1. Zeitler P, Arslanian S, Fu J, et al. . ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes 2018;19 Suppl 27:28–46. 10.1111/pedi.12719
    1. Buchwald H, Estok R, Fahrbach K, et al. . Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56. 10.1016/j.amjmed.2008.09.041
    1. Adams TD, Davidson LE, Litwin SE, et al. . Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 2017;377:1143–55. 10.1056/NEJMoa1700459
    1. Aminian A, Brethauer SA, Andalib A, et al. . Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg 2017;266:650–7. 10.1097/SLA.0000000000002407
    1. Amouyal C, Andreelli F. What is the evidence for metabolic surgery for type 2 diabetes? A critical perspective. Diabetes Metab 2017;43:9–17. 10.1016/j.diabet.2016.06.005
    1. Rubino F, Nathan DM, Eckel RH, et al. . Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Obes Surg 2017;27:2–21. 10.1007/s11695-016-2457-9
    1. Schauer PR, Kashyap SR, Wolski K, et al. . Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567–76. 10.1056/NEJMoa1200225
    1. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219–34. 10.1111/joim.12012
    1. Sjöström L, Peltonen M, Jacobson P, et al. . Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297–304. 10.1001/jama.2014.5988
    1. Schauer PR, Bhatt DL, Kirwan JP, et al. . Bariatric Surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641–51. 10.1056/NEJMoa1600869
    1. Schauer PR, Bhatt DL, Kirwan JP, et al. . Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med 2014;370:2002–13. 10.1056/NEJMoa1401329
    1. RISE Consortium . Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. observations using the hyperglycemic clamp. Diabetes Care 2018;41:1696–706. 10.2337/dc18-0244
    1. Inge TH, Courcoulas AP, Jenkins TM, et al. . Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 2016;374:113–23. 10.1056/NEJMoa1506699
    1. Inge TH, Laffel LM, Jenkins TM, et al. . Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents. JAMA Pediatr 2018;172:452–60. 10.1001/jamapediatrics.2017.5763
    1. Bjornstad P, Hughan K, Kelsey MM, et al. . Effect of surgical versus medical therapy on diabetic kidney disease over 5 years in severely obese adolescents with type 2 diabetes. Diabetes Care 2020;43:187–95. 10.2337/dc19-0708
    1. Reames BN, Finks JF, Bacal D, et al. . Changes in bariatric surgery procedure use in Michigan, 2006-2013. JAMA 2014;312:959–61. 10.1001/jama.2014.7651
    1. Inge TH, Coley RY, Bazzano LA, et al. . Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. Surg Obes Relat Dis 2018;14:1374–86. 10.1016/j.soard.2018.04.002
    1. de Oliveira VLP, Martins GP, Mottin CC, et al. . Predictors of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass in severely obese patients. Obes Surg 2018;28:195–203. 10.1007/s11695-017-2830-3
    1. Courcoulas AP, Yanovski SZ, Bonds D, et al. . Long-Term outcomes of bariatric surgery: a national Institutes of health symposium. JAMA Surg 2014;149:1323–9. 10.1001/jamasurg.2014.2440
    1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887–92. 10.1056/NEJM200006223422507
    1. Concato J, Lawler EV, Lew RA, et al. . Observational methods in comparative effectiveness research. Am J Med 2010;123:e16–23. 10.1016/j.amjmed.2010.10.004
    1. Pratt JSA, Browne A, Browne NT, et al. . ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018;14:882–901. 10.1016/j.soard.2018.03.019
    1. Armstrong SC, Bolling CF, Michalsky MP, et al. . Pediatric metabolic and bariatric surgery: evidence, barriers, and best practices. Pediatrics 2019;144. 10.1542/peds.2019-3223. [Epub ahead of print: 27 Oct 2019].
    1. Davies MJ, D'Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2018;41:2669–701. 10.2337/dci18-0033
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22. 10.1056/NEJMoa1603827
    1. Zinman B, Wanner C, Lachin JM, et al. . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. 10.1056/NEJMoa1504720
    1. Zeitler P, Hirst K, Copeland KC, et al. . Hba1C after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. Diabetes Care 2015;38:2285–92. 10.2337/dc15-0848
    1. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York, NY: Springer, 2000.
    1. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424. 10.1080/00273171.2011.568786

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever